INTRODUCTION
============

Chromosomal DSBs, caused by replication fork disruption, environmental factors or endogenous nucleases are common yet potentially dangerous DNA lesions in all organisms. DNA DSBs are critical lesions that if unrepaired or misrepaired may be lethal for a cell or contribute to its malignant transformation. DSBs can be repaired either by homologous recombination or by non-homologous end joining pathways ([@B1; @B2; @B3; @B4; @B5; @B6]). In this regard, the budding yeast *Saccharomyces cerevisiae* has become the most intensely studied model system for DSB DNA repair.

RecQ proteins comprise a highly conserved family of 3′--5′ DNA helicases that includes the human BLM, WRN, RECQL4 and RECQ5 proteins, as well as Rqh1 from *Schizosaccharomyces pombe* and Sgs1 in *S. cerevisiae* ([@B7; @B8; @B9]). Werner's, Bloom's and Rothmund-Thomson's genome instability syndromes are caused by mutation of the *WRN*, *BLM* and *RECQL4* genes, respectively ([@B10; @B11; @B12]). RecQ DNA helicases have been implicated in several aspects of DNA metabolism ([@B8]), including a recently characterized role in the initial step of homologous recombination in *S. cerevisiae* ([@B13],[@B14]). After a DSB is formed and recognized, Sae2 trims the ends to create a minimally resected intermediate. Sgs1 and Exo1 then rapidly process this intermediate to generate extensive tracts of single-strand DNA that serve as substrates for Rad51 in homologous recombination ([@B13],[@B14]).

Posttranslational modification with the [s]{.ul}mall [u]{.ul}biquitin-[r]{.ul}elated [m]{.ul}odifier (SUMO), is a widespread mechanism for rapid and reversible changes in protein function. Sumoylation occurs by a process that is similar to ubiquitylation. An E1 activating protein (Aos1/Uba2) loads SUMO onto the E2 conjugating enzyme (Ubc9), which in turn transfers SUMO (Smt3 in budding yeast) onto specific lysine residues within target substrates ([@B15]). Sumoylation has recently been reported to regulate Rqh1 activity at telomeres in *S. pombe* ([@B16]). Moreover, WRN, BLM and Sgs1 were all previously shown to be sumoylated ([@B17; @B18; @B19]), although the exact role of this modification in homologous recombination is not completely understood.

In the absence of telomerase, immortalized mammalian cells and yeast may employ recombination-mediated pathways to maintain telomeres, termed alternative lengthening of telomeres (ALT), in mammalian cells ([@B20; @B21; @B22]). Telomerase-negative *S. cerevisiae* overcomes telomere crisis by utilizing one of two Rad52-dependent recombination-mediated pathways, termed Types I and II ([@B23],[@B24]). Type I telomere lengthening requires Rad51, whereas Type II telomere lengthening requires Rad50 and the Sgs1/Top3 complex ([@B25; @B26; @B27; @B28; @B29]). Telomeric repeats in Type II survivors are amplified and often heterogeneous in length, whereas Type I survivors have amplified subtelomeric Y′-elements. Terminal telomeric repeats in human cells using ALT are long and heterogeneous, suggesting that a Type II-like mechanism is used in these pathways ([@B20; @B21; @B22]).

The association of Sgs1 with the Type II recombination pathway prompted us to hypothesize a conserved function of these RecQ helicases in recombination-mediated telomere lengthening. Furthermore, very recently, Rqh1 has been reported to control the fate of dysfunctional telomeres ([@B16]). In this study, we demonstrate that DSBs induced by ionizing radiation (IR) or chemicals, but not replication fork disruption or oxidative stress, promote Sgs1 sumoylation. The major SUMO attachment site in Sgs1 is lysine 621, which lies between the Top3 binding and DNA helicase domains ([@B30],[@B31]). A conservative mutation at this residue reduces Type II telomere--telomere recombination, but does not alter the functions of Sgs1 in DSB repair and homologous recombination at other loci in the genome. This indicates that sumoylation of Sgs1 specifically facilitates telomere--telomere recombination.

MATERIALS AND METHODS
=====================

Yeast strains and plasmids
--------------------------

All the yeast operations were performed by standard methods ([@B32]). STY1525 (YPH499 *SGS1*-13Myc) was constructed by double crossing over the chromosomal *SGS1* gene of YPH499 ([@B24]) with a 13Myc PCR fragment from pFA6a-13Myc-kanMX6 ([@B33]). STY1793 (YPH499 *ubc9-1 SGS1*-13Myc) was obtained by three backcrosses of MR966 *ubc9-1* ([@B34]) with YPH499, *ULP1* and *ULP2* plasmids, which were kindly provided by Dr Mark Hochstrasser ([@B35],[@B36]). pRS306-*SGS1* was constructed as described below. Point mutations were introduced into pRS306-*SGS1* using QuikChange site-directed mutagenesis (Stratagene). To generate chromosomal *sgs1* mutants, pRS306-*sgs1* mutants were linearized by AflII and transformed into *SGS1* strains, and *URA3* pop-out mutants were identified from 5-FOA-resistant colonies using PCR analysis. Both E3 deletion mutants were purchased from yeast deletion library (Invitrogen). The *sgs1::HIS3* mutation was constructed by transforming these strains with an *sgs1::HIS3* PCR fragment amplified from STY680 (*sgs1*::*HIS3*) ([@B27]) genomic DNA using an *SGS1* upstream and downstream primer pairs. YPH499 *exo1* strains were generated by transplacement of the YPH499 *EXO1* locus with an *exo1::kanMX6* fragment amplified from yeast deletion library (Invitrogen). STY1881 (YPH500 *top3::URA3*) was generated using a *URA3* fragment that was PCR-amplified from pMPY-3xHA ([@B37]) using oligonucleotides with sequences homologous to the *TOP3* upstream and downstream regions. This knockout fragment was then introduced into the indicated strains. For the inter-chromosomal recombination assay, MR966 and MR93-28c ([@B34]) were manipulated independently and mated to obtain diploid cells. The *sgs1::URA3* mutation was generated by transforming strains with an *sgs1::URA3* PCR fragment amplified using primers with sequences homologous to the *SGS1* up- and downstream regions. pRS316-*SGS1* was a backbone exchange construct of pRS314-*SGS1* ([@B27]). A SacII-SacI fragment containing the C-terminal *SGS1* and 13Myc regions was cloned into the SacII/SacI-digested pRS316-*SGS1* to generate pRS316-*SGS1*-13Myc. pRS306-*SGS1* for two-step gene replacement was cloned by ligation of an XhoI/BamHI fragment from pRS316-*SGS1*-13Myc into pRS306. pGEX-4T-*SGS1* (410--713) was constructed by ligating the BamHI/PstI-Klenow-treated fragment containing the aa 410--713 of Sgs1 into the BamHI/SmaI-digested pGEX4T-1 (GE). All primer sequences for PCR and mutagenesis are available upon request.

Western blotting analysis and *in vitro* sumoylation assay
----------------------------------------------------------

Early log phase cultures were grown to an OD~600~ of 0.5 and extracts were prepared for western blotting using an anti-Myc antibody. The signal was quantitated using ImageQuant software Version 5.2 (GE). The His~6~-tagged yeast SUMO E1, E2 and Smt3 expression plasmids were kindly provided by Drs Günter Blobel ([@B38]) and Ting-Fang Wang ([@B39]). Purification of these enzymes was performed as described ([@B38]). Recombinant GST-Sgs1 was expressed in the BL21 strain and purified according to the manufacturer (GE). For the *in vitro* sumoylation assay, 1 µg of SUMO, 2 μg of Aos1/Uba2, 2.5 μg of Ubc9 and 5 μg of substrate were incubated at 30°C for 2 h. Reactions were performed in 50 μl reaction buffer containing 50 mM HEPES (pH 7.5), 100 mM NaCl, 10 mM MgCl~2~, 20 μg bovine serum albumin, 5 mM Tris, 0.1 mM DTT and 5 mM ATP.

Spot dilution assay
-------------------

For the spot dilution assay, early log phase cultures were adjusted to an OD~600~ of 0.5 and serial 5-fold dilutions were made in sterial water. Five microliters were spotted onto YPD plates, followed by exposure to different temperatures, ionizing radiation (IR), or UV light. Alternatively, cells were spotted onto YPD plates containing various concentrations of methyl methanesulphonate (MMS), ethyl methanesulfonate (EMS), bleomycin or hydroxyurea (HU). Drug-containing plates were prepared 2 days before use.

Yeast telomere analysis
-----------------------

Liquid cultures were generated by inoculating spore colonies from the freshly dissected spores into 10 ml of liquid YEPD medium. Cultures were diluted repeatedly 1:10 000 into fresh medium and grown at 30°C for 48--72 h to reach the stationary phase. Solid-media experiments were performed by repeatedly streaking spore colonies from the dissection plates onto YEPD plates. To quantify the ratio of Type I versus Type II survivors, spore cells were serially restreaked onto YEPD medium as described ([@B40]) to obtain survivors on solid media. Genomic DNA was digested with a mixture of HaeIII, HinfI and MspI, and Southern blot analysis was performed using a telomere probe as previously described ([@B40]).

Competition assay for formation of survivors
--------------------------------------------

The *tlc1Δ* and *tlc1Δ sgs1-K621R* cells were taken from freshly dissected spore colonies and mixed in a 50:50 ratio in YEPD medium. Following growth to stationary phase, cultures were diluted 1:10 000 every 2 days, for 12 days. Genomic DNA was extracted from cultures at the indicated time points and subjected to quantitative real-time PCR to determine the genomic background of *SGS1* using specific primers*.* The tubulin gene was used as an internal control. The primer specific for wild-type *SGS1* is GACTAACACTGGATTTCTCCCTTT and for *sgs1-K621R* is GACTAACACTGGATTTCTCCCTT[C]{.ul} (the underline indicates the difference in the mutant). Control experiments showed that the primers did not cross-amplify non-specific products (data not shown). Data were expressed as a percentage of the sum of the signals amplified from *SGS1* and *sgs1-K621R* in individual cultures. Other primer sequences for PCR are available upon request.

Assays for recombination frequency
----------------------------------

Recombination between direct repeats was assayed in the indicated strains following transformation with pRS314-Lu ([@B41]). Fresh transformants were first patched onto YEPD plates for 24 h. Cells were then resuspended in water and diluted onto synthetic complete (SC) plates (with or without leucine) to score recombination frequency. To determine the inter-chromosomal recombination frequency between *his1-1* and *his1-7* heteroalleles, independent colonies of indicated strains were patched on YEPD plates for 24 h. Cells were then resuspended in water and diluted onto SC plates (with or without histidine) containing 0 or 0.01% of MMS to monitor viability and recombination frequency. It is worth noting that this assay could not distinguish between gene conversion and recombination.

rDNA recombination
------------------

The frequency of intra-chromosomal rDNA recombination was monitored by measuring the frequency of loss of the *URA3* marker in strain STY1880 (*rDNA::URA3 sgs1::HIS3*). STY1880 was constructed from strain W979-3B (*rDNA::URA3*) as described above ([@B42]). Strains were then transformed with pRS314-based plasmids carrying either wild-type or mutant *SGS1* genes. Five independent transformants of each genotype were grown to stationary phase in 2 ml of non-selective medium and then diluted appropriately and spread onto SC plates with or without 5-FOA.

RESULTS
=======

Lysine 621 is the major sumoylation site of Sgs1
------------------------------------------------

The finding that Sgs1 was sumoylated ([@B19]) prompted us to study its significance on the cellular functions of Sgs1. In order to optimize our ability to detect this modification, Sgs1 was chromosomally tagged with Myc~13~. We found that treatment of yeast cells with 0.3% MMS for 30 min induced a slower migrating form of Sgs1 as detected by immunoblot analysis ([Figure 1](#F1){ref-type="fig"}A). The size of this mobility shift is consistent with the addition of one SUMO moiety (Smt3, ∼11 kDa). The fact that the slower band required wt SUMO E2 activity (*UBC9*) and was sensitive to overexpression of either de-sumoylase *ULP1* or *ULP2* ([@B35],[@B36]) ([Figure 1](#F1){ref-type="fig"}B) suggests that the upper band is the sumoylated form of Sgs1. Figure 1.The K621 residue of Sgs1 is critical for its sumoylation. (**A**) Sgs1 was chromosomally tagged with Myc~13~. Cells were grown to early log phase and subjected to various dosages and times of MMS treatment. Lysates were extracted and western blot analysis was performed using an anti-Myc antibody. (**B**) Wild-type and *ubc9-1* strains overexpressing the indicated desumoylases were treated with or without 0.3% of MMS for 2 h and treated as above. (**C**) The *sgs1Δ*, *sgs1Δ siz1Δ* and *sgs1Δ siz2Δ* strains containing pRS316-*SGS1*-Myc~13~ were subjected to MMS treatment as described above. (**D**) Schematic representation of the position of SUMO consensus motifs and domains within Sgs1. T, Top3-interacting domain; A, acidic region; R, RecQ C-terminal homology region; H, Helicase and RNaseD C-terminal region. (**E**) Wild-type, *sgs1-K621R* and *sgs1-K831R* cells were subjected to MMS treatment as described above. Sumoylated Sgs1 is marked with an asterisk. (−) and (+) refers to treatment without or with MMS, respectively. (**F**) Recombinant Aos1/Uba2 (E1), Ubc9 (E2), Smt3 and purified GST-Sgs1(410--713) were incubated at 30°C for 2 h in the absence (−) or presence (+) of ATP as described in the 'Materials and Methods' section. Western blot analysis was then performed using an anti-GST antibody.

There are three major SUMO E3 ligases in budding yeast (Siz1, Siz2 and Mms21) ([@B43]), and a previous study showed that Mms21 was not required for the sumoylation of Sgs1 ([@B19]). Deletion of *SIZ1* or *SIZ2* did not significantly reduce the level of sumoylated Sgs1 ([Figure 1](#F1){ref-type="fig"}C). This suggests that *SIZ1* and *SIZ2* are redundant in promoting the conjugation of SUMO onto Sgs1.

There are three SUMO consensus sites (ΨKxE) ([@B44]) within Sgs1 (aa 175, 621 and 831, [Figure 1](#F1){ref-type="fig"}D). To identify the *in vivo* sumoylation site of Sgs1, each of these lysines was mutated to arginine. Sgs1 sumoylation was abolished by the *K621R* mutation, diminished by *K831R* and unaffected by *K175R* ([Figure 1](#F1){ref-type="fig"}E; data not shown). This indicates that K621 is essential for sumoylation *in vivo*. To confirm that K621 is an authentic site for sumoylation, a fragment of Sgs1 containing this residue was purified from *E. coli* and used in an *in vitro* sumoylation assay. As shown in [Figure 1](#F1){ref-type="fig"}F, the wild-type Sgs1 fragment was efficiently sumoylated, whereas protein containing the K621R mutation was not. These data indicate that K621 is the major sumoylation site of Sgs1.

Sumoylation of Sgs1 occurs in a lesion-dependent manner
-------------------------------------------------------

We next examined the conditions necessary for the induction of Sgs1 sumoylation. Modification of Sgs1 was rarely observed in wild-type cells grown under normal conditions, but a fraction of sumoylated protein appeared after culturing the cells in the presence of at least 0.3% MMS ([Figure 1](#F1){ref-type="fig"}A). We, therefore, tested whether sublethal concentrations of the following DNA-damaging agents induced Sgs1 sumoylation: bleomycin and IR (which lead to DSB formation), hydroxyurea (which results in replication forks stalling) and H~2~O~2~ (which induces oxidative stress). In contrast to hydroxyurea- or H~2~O~2~-treated cells, Sgs1 sumoylation was observed because of treatment with bleomycin, IR or EMS ([Figure 2](#F2){ref-type="fig"}A). These results indicate that Sgs1 sumoylation is elicited specifically under conditions that generate DSBs. Figure 2.Sumoylation of Sgs1 occurs in a lesion-dependent manner. (**A**) Cells were grown to early log phase and treated with either IR or the indicated concentrations of genotoxic agents for 2 h. Lysates were harvested and analyzed by western blot analysis as described in [Figure 1](#F1){ref-type="fig"}. The efficiencies of damage levels were confirmed by Rad53 activation (bleomycin, IR, EMS and HU) or survival rate (H~2~O~2~) after treatment (data not shown). (**B**) Cells of the indicated genotype were grown to early log phase, serially diluted in 5-fold increments and spotted onto YPD plates containing the indicated levels of MMS. The plates were photographed after 2 days at 30°C.

We next asked whether Sgs1 sumoylation was important for growth in the absence of DNA damage. Relative growth rates were determined by an assay in which two types of cells are mixed and scored for their ability to proliferate. Wild-type Leu^−^ cells were mixed at a 50:50 ratio with *sgs1Δ*, *sgs1-K621R* or *sgs1-K831R* Leu^+^ cells of the same mating type and allowed to grow without selection. Cultures were diluted every day, and after 7 days they were plated onto selective and nonselective media to measure the populations in the cultures. Data collected in this manner showed that *sgs1Δ* cells had reduced proliferative capacity. However, s*gs1-K621R* and *sgs1-K831R* cells gave results that were indistinguishable from those of the wild-type ([Supplementary Figure S1](http://nar.oxfordjournals.org/cgi/content/full/gkp1008/DC1)). Thus, sumoylation of Sgs1 does not provide any growth advantage to yeast cells.

Because a major function of Sgs1 is to cope with the genotoxic insults, we tested whether sumoylation of Sgs1 contributes to DNA damage tolerance. Deletion of *SGS1* confers sensitivity to DNA damage, a phenotype that is often attributed to defects in DNA repair ([@B45]). To determine if *sgs1-K621R* cells have similar repair defects, we tested their sensitivity to MMS, bleomycin and hydroxyurea by spotting serially diluted cells onto plates containing these drugs ([Figure 2](#F2){ref-type="fig"}B, [Supplementary Figure S2B](http://nar.oxfordjournals.org/cgi/content/full/gkp1008/DC1)). Alternatively, cells were treated with MMS before plating ([Supplementary Figure S2A](http://nar.oxfordjournals.org/cgi/content/full/gkp1008/DC1)), or exposed to UV light immediately after plating ([Supplementary Figure S2B](http://nar.oxfordjournals.org/cgi/content/full/gkp1008/DC1)). While *sgs1Δ* cells were MMS, bleomycin, hydroxyurea and UV sensitive, the *sgs1-K621R* and *sgs1-K831R* cells grew as well as wild-type cells under these treatments ([Figure 2](#F2){ref-type="fig"}B; [Supplementary Figure S2](http://nar.oxfordjournals.org/cgi/content/full/gkp1008/DC1)). Diploid *sgs1Δ* cells display heightened sensitivity to these agents relative to haploid strains ([@B34]). Therefore, we tested MMS sensitivity in homozygous diploid cells. Again, diploid mutant cells showed wt levels of DNA damage tolerance ([Figure 2](#F2){ref-type="fig"}B). Further, Exo1 and Sgs1 have been found to collaborate in DNA DSB processing ([@B13],[@B14]). We, therefore, tested whether deletion of *EXO1* would amplify the contribution of Sgs1 sumoylation in DNA repair, by conducting similar experiments in the *exo1* background. As shown in [Figure 2](#F2){ref-type="fig"}B, *exo1 sgs1-K621R* and *exo1 sgs1-K831R* cells displayed the same MMS sensitivity as *exo1* cells. Altogether, these data demonstrate that, unlike *sgs1Δ* cells, *sgs1-K621R* cells have wild- or near-wild-type abilities to repair exogenously generated DNA damage.

Sgs1 K621 sumoylation modulates telomere--telomere recombination
----------------------------------------------------------------

Previous studies have shown that Sgs1 deficiency eliminates telomere--telomere recombination in telomerase-deficient cells ([@B25],[@B27; @B28; @B29]). We, therefore, analyzed whether the loss of Sgs1 sumoylation similarly influences this phenotype. Freshly generated *tlc1Δ* (telomerase deficient) *sgs1* spore clones were repeatedly grown to saturation in liquid culture for analysis of telomeric recombination patterns by Southern blot. As shown in [Figure 3](#F3){ref-type="fig"}, we analyzed recombinants from *tlc1Δ*, *tlc1Δ sgs1Δ*, *tlc1Δ sgs1-K621R* and *tlc1Δ sgs1-K831R* spores. Compared with the *tlc1Δ* and *tlc1Δ sgs1-K831R* strains, which displayed the Type II telomere--telomere recombination pattern after several dilutions, such a pattern was absent in the *tlc1Δ sgs1Δ* and *tlc1Δ sgs1-K621R* strains. Instead these cells produced the signal expected for Y′--Y′ (Type I) recombination. Moreover, the appearance of this Type I signal was significantly delayed relative to the onset of Type II recombinants. Thus, Sgs1 K621 sumoylation is functionally important for telomere--telomere recombination. Figure 3.Sgs1 K621 sumoylation promotes telomere--telomere recombination. Telomerase deficient (*tlc1Δ*) strains carrying the indicated *SGS1* alleles were repeatedly diluted and grown to saturation in liquid culture. Following the indicated rounds of growth, cells were harvested and genomic DNA was isolated. DNA was then digested and Southern blotted with a telomeric probe as described in the 'Materials and Methods' section. Data shown here are representative of three or more experiments using independent spore clones. The increased intensity of the smallest band in panels 2 and 3 is due to Y′--Y′ amplification from Type I survivors.

Sgs1 K621 sumoylation promotes the generation of Type II survivors
------------------------------------------------------------------

Since Sgs1 sumoylation is functionally important for telomeric recombination, we tested whether the modification stimulates Type II telomere--telomere recombination or whether it represses Type I Y′--Y′ amplification. Either mechanism would lead to the observed reduction in Type II recombinants in *tlc1Δ sgs1-K621R* cells ([Figure 3](#F3){ref-type="fig"}). To distinguish between these two possibilities, a competition assay for survivor formation was performed. Cells from *tlc1Δ* and *tlc1Δ sgs1-K621R* spore colonies were mixed at a 50:50 ratio, and repeatedly diluted and grown to saturation. Quantitative PCR was used to show that, over time, the proliferation of the *sgs1*-K621R strain was compromised relative to the *tlc1Δ* single mutant ([Figure 4](#F4){ref-type="fig"}A). The reduced survival of this strain indicates that telomeric healing is diminished and suggests that sumoylation promotes Type II events. Figure 4.Sgs1 K621 sumoylation promotes Type II telomere recombination. (**A**) A growth competition assay was performed on *tlc1Δ* and *tlc1Δ sgs1-K621R* strains to test the role of Sgs1 sumoylation in the absence of telomerase. After the indicated number of rounds of growth, genomic DNA was obtained and the fraction of cells carrying each allele was determined by real-time PCR. Plotted on the *Y*-axis is the average allele frequency from three independent experiments ± SDs. Significant differences (*P* \< 0.001), as determined by the student's *t*-test, are indicated by asterisks. (**B**) Freshly isolated spores of indicated strains were repeatedly streaked onto YPD plates and grown for 3 days. Growth from the first four streaks are shown.

Consistent with this interpretation, we performed senescence assays on solid media and isolated one hundred *tlc1Δ sgs1-K621R* survivors. DNA was then prepared from individual survivors and the telomere pattern was determined by Southern blot analysis. Significantly, all of the *sgs1-K621R* survivors (100 of 100) displayed the Type I pattern (data not shown). In contrast, *tlc1Δ* single mutants generate both Types I and II survivors ([@B40]). Taken together, these data indicate that Sgs1 K621 sumoylation stimulates Type II recombination.

To confirm this idea, we relied on the fact that Rad51 is required for Type I Y′--Y′ amplification and that *tlc1Δ rad51Δ* strains generate exclusively Type II survivors ([@B24],[@B26]). If Sgs1 sumoylation is important for Type II telomere--telomere recombination, then *sgs1-K621R* should have an inhibitory effect on *tlc1Δ rad51Δ* survivors. The appropriate strains were generated from freshly dissected spores and examined by serial single-colony restreaking on solid media. As expected, *tlc1Δ* and *tlc1Δ sgs1* strains showed a cellular senescence phenotype on the third restreak ([Figure 4](#F4){ref-type="fig"}B), while the *tlc1Δ rad51Δ sgs1Δ* spores senesced at the first restreak and completely lost viability at the second restreak. These results indicate that the triple mutation prevents all three (telomerase, Types I and II) pathways for telomere maintenance and blocked survivor formation. While the *tlc1Δ rad51Δ* cells senesced at the first restreak and survivors developed at the second restreak, the *tlc1Δ rad51Δ sgs1-K621R* strain showed cellular senescence phenotype at both the first and second restreaks, and survivors developed at the third restreak ([Figure 4](#F4){ref-type="fig"}B). This delayed survivor formation in the *tlc1Δ rad51Δ* background is consistent with the observation that the Sgs1-K621R protein is unable to stimulate Type II recombination ([Figure 4](#F4){ref-type="fig"}A). Thus, the *sgs1-K621R* mutation reduces telomere--telomere recombination for telomeric maintenance and subsequently delays survivor formation in the *tlc1Δ rad51Δ* background.

Sumoylation of Sgs1 is dispensable for other homologous recombination pathways
------------------------------------------------------------------------------

Sgs1 acts both early in the homologous recombination pathway (i.e. during 5′-end resection), and late (i.e. dissolution of hemi-catenated products) ([@B13],[@B14]). To test whether Sgs1 sumoylation plays a role in homologous recombination, we examined the phenotype of the sumoylation-defective alleles in several recombination assays. To examine direct repeat recombination, we took advantage of a plasmid ([@B41]) containing a duplicated 600-bp internal fragment of *LEU2*, separated by intervening sequences ([Figure 5](#F5){ref-type="fig"}A). If Sgs1 sumoylation is required for direct repeat recombination, the *sgs1-K621R* mutation would be expected to have phenotype like that of *sgs1Δ* cells. As shown in [Figure 5](#F5){ref-type="fig"}A, both *sgs1-K621R* and *sgs1-K831R* mutants exhibited recombination frequencies similar to that of wild-type cells. And consistent with previous reports ([@B46]), a hyper-recombination phenotype was observed in *sgs1Δ* cells ([Figure 5](#F5){ref-type="fig"}A). Based on these results, sumoylation of Sgs1 does not participate in the regulation of homologous recombination by direct repeats. Figure 5.Recombination phenotypes of SUMO-deficient Sgs1. (**A**) Recombination frequency of direct repeat was determined by the pRS314-Lu system ([@B62]). Recombination frequencies were calculated using the median method of Lea and Couison ([@B63]). (**B**) Schematic representation of inter-chromosomal recombination between *his1*-*1* and *his1*-*7* heteroalleles in diploid cells. Data shown here are the averages of four independent experiments (*n* = 12). Recombination-deficient *rad52* mutant was served as a negative control. (**C**) MMS-induced inter-chromsomal recombination frequency was evaluated using the *his1-1/his1-7* heteroallelic system described in (B). Data here are the fold enrichments upon 0.01% MMS treatment. (**D**) Slow growth phenotype was examined in strains combined with the *top3* deletion. Exponentially growing cells were 5-fold serially diluted and spotted onto YPD plates.

Rad52 is a key player in most homologous recombination processes, including gene conversion, reciprocal exchange, single-strand annealing, telomere recombination and break-induced replication ([@B47]). Rad52 is also sumoylated, and mutation of its sumoylation sites has a minor effect on homologous recombination. However, inter-chromosomal recombination between heteroallelic markers is regulated by Rad52 sumoylation ([@B48],[@B49]). We therefore tested whether Sgs1 sumoylation affected recombination between the *his1*-*1* and *his1*-*7* heteroalleles. However, as shown in [Figures 5](#F5){ref-type="fig"}B and C, *sgs1*-*K621R* cells showed recombination frequencies that were similar to those of wild-type cells, including events induced by MMS. In contrast, the *sgs1* null mutant showed severe defects in these assays ([@B50]).

It has been reported that the role of Sgs1 in DNA replication can be uncoupled from its role in homologous recombinational repair by mutating certain residues in the acidic region of Sgs1 ([Figure 1](#F1){ref-type="fig"}D) ([@B51]). Since the K621 residue localizes to this region, we tested whether its sumoylation is required for Sgs1 to promote DNA replication. Deletion of *SGS1* suppresses the mitotic cell cycle delay of a *top3* mutant ([@B42]), and this implies that Sgs1 generates an intermediate that is normally resolved by Top3 in the S phase. However, as shown in [Figure 5](#F5){ref-type="fig"}D, the slow growth of *top3Δ* cells was not suppressed by the *sgs1-K621R* mutation. Thus, sumoylation of Sgs1 does not influence the repair of DNA replication intermediates. Taken together, these assays demonstrate that sumoylation of Sgs1 is specifically required for telomere--telomere recombination, but is dispensable for other types of homologous recombination and replicative repair.

Sumoylation of Sgs1 is not involved in rDNA recombination
---------------------------------------------------------

Since Sgs1 sumoylation is required for Type II telomere--telomere recombination but not other types of homologous recombination, we speculated that this might be due to its specialized telomeric heterochromatin. For example, sumoylation of Sgs1 might be required for the helicase to gain access to telomeric DNA that is maintained in the form of heterochromatin. To test the generality of this idea, we assayed recombination at the rDNA array because of its heterochromatic character ([@B52],[@B53]). A *URA3* marker was inserted in the rDNA locus of an *sgs1Δ* strain, and wild-type or mutant *SGS1* plasmids were transformed into this strain. The frequency of rDNA recombination was determined by excision of the *URA3* marker. As shown in [Figure 6](#F6){ref-type="fig"}, no difference in the frequency of rDNA recombination was observed between the wild-type and *sgs1-K621R* strains. Based on these findings, we conclude that Sgs1 sumoylation does not play a general role in the regulation of homologous recombination, but specifically promotes Type II telomere--telomere recombination. Figure 6.SUMO-defective Sgs1 does not affect rDNA recombination. An *sgs1* strain with the *URA3* insertion in the rDNA locus was transformed with a CEN-based plasmid carrying wild-type *SGS1* or *sgs1* mutants. The rDNA recombination rate of each strain was calculated as described in [Figure 5](#F5){ref-type="fig"}A. Data here are the averages of three independent experiments.

DISCUSSION
==========

Several RecQ DNA helicases have been shown to be sumoylated ([@B17; @B18; @B19]). However, the exact function of this modification in homologous recombination is not well understood. Here, we have show that Sgs1 sumoylation is induced in response to DSBs, and that K621 is the major site of Sgs1 sumoylation. We were surprised to find that sumoylation is dispensable for most biological functions of Sgs1, including homologous recombination and promoting *top3Δ* slow growth. However, sumoylation of K621 is essential for promoting Type II telomere--telomere recombination. While it is not clear whether sumoylation is required for the human RecQ helicases to carry out homologous recombination, our data are consistent with the very recent findings that Rqh1 sumoylation is crucial for determining the pathway for repair of dysfunctional telomeres in *S. pombe* ([@B16]).

In budding yeast, Rad52, Smc5/6 and Sgs1 are all necessary for homologous recombination, and are all sumoylated. It has been suggested that concurrent sumoylation of several homologous recombination-related proteins may be required to orchestrate the efficient execution of DNA damage-induced homologous recombination ([@B48]). In that respect, it is important to note that many studies have found a link between specific subnuclear localization and protein modification by SUMO ([@B18],[@B38],[@B54]). Thus, upon DNA damage, multiple components of the homologous recombination machinery may necessarily co-localize at sites of sumoylation where some of them undergo SUMO modification to specifically alter their enzymatic activity. For example, Rad52 sumoylation, which is triggered by DSBs in an MRX-dependent manner, modifies Rad52 activity in inter-chromosomal recombination between heteroallelic markers ([@B48]). This mechanism appears to be conserved in human cells, where RecQ helicases and the recombination proteins RAD51, RPA and PML co-localize to PML bodies upon IR treatment ([@B55]), and sumoylation is required for the formation of the nuclear foci of these repair proteins ([@B54],[@B56]). In our hands, however, Sgs1 sumoylation was not required for most of its roles in homologous recombination. One explanation for this result, although unattractive, is that Sgs1 sumoylation occurs non-specifically because of its close association with other recombination factors and an indiscriminate sumoylation machinery. However, it is more likely that the small fraction of Sgs1 molecules that is modified by SUMO in response to DSBs represents a pool of proteins whose novel functions are redundant with other recombination proteins or pathways. For example, in the absence of sumoylation, Sgs1-K621R may be activated for recombinational repair by back-up pathways or other posttranslational modifications. These modifications may be transient or constitute a pool size that is beyond our detection limit. If this second modification is essential for activating Sgs1-K621R, then its loss should result in synthetic interactions with *sgs1-K621R*. Thus, a screen for synthetic interactors with *sgs1-K621R* would be one approach to identify these other proteins or pathways.

If sumoylation does not contribute to the major roles of Sgs1 in homologous recombination, how does Sgs1 sumoylation specifically promote telomere--telomere recombination? A plausible explanation is that sumoylation is required to localize Sgs1 to telomeres for telomere--telomere recombination. As a mechanism for redistribution, sumoylation may provide better accessibility for Sgs1 to act on its telomeric substrates. In support of this idea, it has been shown that abolition of the Pli1 SUMO E3 ligase leads to defects in telomere clustering, silencing and length regulation in *S. pombe* ([@B57]). The ability of global sumoylation levels to influence telomeres in this way argues that sumoylation is an important player in telomere maintenance. Similarly, the SMC5/6 complex facilitates telomere--telomere recombination and elongation in ALT cells by promoting ALT-associated PML body formation via the sumoylation of multiple telomere binding proteins ([@B58]). And intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is also regulated by SUMO modification ([@B18]). All of these findings point to the possibility that sumoylation mediates the localization of multiple recombination proteins, including RecQ helicases, to telomeres to execute telomere--telomere recombination.

Sgs1 and its ortholog Rqh1 mediate the restart of stalled replication forks in both *S. cerevisiae* ([@B59]) and *S. pombe* ([@B60]). If telomeric recombination is initiated by the repair of stalled or collapsed replication forks, then it would be expected that a deficiency in Sgs1 would impact the frequency, and perhaps the mechanism, of telomere--telomere recombination. In addition, telomeric heterochromatin may present unique challenges to replication forks or their repair. For example, the telomere-specific phenotype observed here might be due to the fact that telomeric chromatin is actively repressed by Rap1 and other factors ([@B61]). Our data would seem to argue against this possibility since rDNA recombination was not modulated by Sgs1 sumoylation. However, the requirements for rDNA heterochromatin are not identical to those at the telomere ([@B52],[@B53]). Thus, it remains a possibility that the strand transfer reactions that occur during telomere--telomere recombination must overcome obstacles not found in euchromatin or the rDNA. Our data suggests that Sgs1 sumoylation is involved in dealing with these challenges, perhaps by ensuring that the Sgs1 complex is targeted to these recombination sites.

Amino acid sequence alignment of the Sgs1, Rqh1 and BLM orthologs reveals a RecQ DNA helicase domain that is highly conserved, and an N-terminal domain of about 650 amino acids that shows little if any sequence conservation ([Supplementary Figure S3](http://nar.oxfordjournals.org/cgi/content/full/gkp1008/DC1)). It is interesting to note that each of the sumoylation sites that have been identified in these three proteins are located in different domains of the protein ([Supplementary Figure S3](http://nar.oxfordjournals.org/cgi/content/full/gkp1008/DC1) and [Figure 1](#F1){ref-type="fig"}D). This indicates that while sumoylation may be a conserved mechanism for modifying these RecQ helicases, there is no requirement that SUMO be conjugated to the same residue or even the same domain of the protein. Further studies will be needed to determine how sumoylation of the BLM orthologs affects each of their enzymatic activities and nuclear distribution. It is expected that such studies will shed light on whether the mechanism of SUMO modification is functionally conserved between these organisms.
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